Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia

• Status: Completed
• Trial end date: 2017-07-30
• Target enrollment: 0
• Participant gender: All

Summary

To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bayer

Criteria

Inclusion Criteria:

• Male or female subjects aged >/=18 years

• Subjects with a histologically or cytologically confirmed acute leukemia who are refractory to or have exhausted all available therapies

• Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2

• Life expectancy of at least 12 weeks

• Adequate liver and renal functions as assessed by the following laboratory requirements to be conducted within 14 days before the first dose of study drug:

• Total bilirubin
• Alanine aminotransferase (ALT) and aspartate aminotransferase (AST)ULN (
• International normalized ratio (INR)
• Estimated glomerular filtration rate (eGFR) >/=50 mL/min per 1.73 m2 according to the Modification of Diet in Renal Disease Study Group (MDRD) formula

• Negative serum or urine pregnancy test must be obtained within 7 days before the first dose of study drug in women of childbearing potential. Negative results must be available before study drug administration

• Women and men of reproductive potential must agree to use highly effective contraception when sexually active. This applies for the period between signing of the informed consent and 30 days after the last administration of study drug. Highly effective contraception includes a hormonal contraception with implants or combined oral contraceptives, certain intrauterine devices, bilateral tubal ligation, hysterectomy, or vasectomy of the partner. In addition, the use of condoms for subjects or their partners is required.

Exclusion Criteria:

• Known hypersensitivity to the study drug or excipients of the preparation or any agent given in association with this study

• History of cardiac disease including congestive heart failure New York Heart Association (NYHA) Class >/=III, unstable angina (anginal symptoms at rest) or new-onset angina (within the last 6 months) or myocardial infarction within the past 6 months or cardiac arrhythmias requiring anti-arrhythmic therapy except for beta-blockers and digoxin; evidence for uncontrolled coronary artery disease (e.g. major regional wall motion abnormalities on baseline echocardiography or a left ventricular ejection fraction (LVEF) <45%)

• Previous pulmonary embolism within 12 months before study entry

• Uncontrolled hypertension defined as systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg, despite optimal medical management and stable antihypertensive treatment for more than 7 days before the first dose of study drug

• Moderate or severe hepatic impairment, i.e. Child-Pugh class B or C

• Known history of human immunodeficiency virus (HIV) infection

• Chronic or active hepatitis B or C, requiring antiviral therapy

• Serious, uncontrolled infection requiring systemic antibiotic, antifungal or antiviral therapy

• Uncontrolled meningeal leukemia

• Prior allogeneic hematopoietic stem cell transplant withindose of study drug (Subjects must have completed immunosuppressive therapy before enrollment.